Abstract:This study aimed to assess the impact of adding pancreatin (a pancreatic enzyme derivative) to standard treatment on patients diagnosed with Irritable Bowel Syndrome (IBS) and Type 2 Diabetes Mellitus (T2DM). IBS and T2DM frequently coexist, leading to significant gastrointestinal symptoms and a decrease in quality of life. Gastrointestinal symptoms arising in T2DM patients present challenges in management for both clinicians and patients. Standard treatments may not fully address these symptoms. Recent studies suggest that pancreatic enzyme replacement therapy may offer additional benefits. This study investigates whether adding pancreatin to standard treatment can improve gastrointestinal outcomes in this patient population. Conducted as a prospective observational study, the research involved patients diagnosed with IBS according to Rome IV criteria and having concomitant T2DM. The patients were divided into two groups: one receiving standard dual treatment (otilinium bromide + simethicone) and the other receiving a triple therapy including a pancreatin derivative in addition to the standard treatment. Various clinical scores and measurements, including Visual Analog Scale (VAS), Bristol Stool Chart (BSC), Irritable Bowel Syndrome-Severity Scoring System (IBS-SSS), and Irritable Bowel Syndrome Quality of Life Instrument (IBS-QOL), were assessed before and after treatment. The study comprised 121 patients, with a median age of 41 years (interquartile range [IQR] 38–48), of whom approximately 70.2% were female. Fifty-eight patients (47.9%) received dual therapy, while sixty-three patients (52.1%) received triple therapy. Before treatment, both groups exhibited similar pre-treatment Bristol stool scale results: normal (39.7% and 49.2%) and constipation (37.9% and 31.7%) in the dual and triple therapy subgroups, respectively ( p > 0.05). Post-treatment, the triple therapy group showed a significantly higher proportion of normal cases on the Bristol stool scale (82.5%) compared to the dual therapy group (44.8%) ( p < 0.001). After treatment, the triple therapy group demonstrated statistically significant improvements in VAS score ( p < 0.001), IBS-SSS ( p < 0.001), and IBS-QOL ( p < 0.001) compared to the dual therapy group. There were no significant differences between groups in BMI, HbA1c levels, duration of diabetes, or diabetes treatment at baseline ( p > 0.05 for all parameters). The findings suggest that adding pancreatin to standard therapies significantly enhanced the quality of life for patients with both IBS and T2DM, demonstrating improvements across various symptom measurements and indicating the potential benefits of this supplementary therapy in managing gastrointestinal symptoms in this population. Further studies are warranted to explore its broader clinical implications and mechanisms of action.

Doxepin(71 Patients) Vs Pancreatin (32 Patients) in Treatment of Irritable Bowel Syndrome

Pinaverium Bromide Combined with Bifid Triple Viable and Doxepin Therapy in Diarrhea-Dominant Irritable Bowel Syndrome

SF-36 quality of life in effectiveness ssessment for irritable bowel syndrome

Treatment of Irritable Bowel Syndrome with Drotaverine Hydrochloride: A Multicentre Clinical Trial

Efficacy of different probiotic protocols in irritable bowel syndrome: A network meta-analysis.

[Probe into Sleep Quality in the Patients with Irritable Bowel Syndrome].

Clinical Efficacy of Glutamine in the Treatment of Irritable Bowel Syndrome

Psychological Factors May Affect the Quality of Life in Irritable Bowel Syndrome Patients More Than the Gut Itself? A Multicenter Cross‐sectional Study

[Clinical Efficacy Observation of Heat-Sensitive Moxibustion with Different Doses for Irritable Bowel Syndrome].

A Probiotic Treatment Containing Lactobacillus, Bifidobacterium and Enterococcus Improves IBS Symptoms in an Open Label Trial

Treatment of factors that related to diarrhea predominant irritable bowel syndrome

Clinical Observation on the Combination of Bifid Tetragenous Viable Bacteria Tablets and Trimebutine Maleate Capsules to Treat the IBS

Study on clinical significance of different subgroups of irritable bowel syndrome patients in Zhejiang province

Intestinal Microecology and Quality of Life in Irritable Bowel Syndrome Patients

The effect of adding pancreatin to standard otilinium bromide and simethicone treatment in type 2 diabetes mellitus patients with irritable bowel syndrome

A clinical trial of fFluoxetine and Paroxetine for the treatment of the irritable bowel syndrome

Some patients with irritable bowel syndrome may have exocrine pancreatic insufficiency

Short-term and Medium-term Clinical Effect of Liver Dispersing with Spleen Strengthening on Irritable Bowel Syndrome Dominated by Diarrhea

Comparative effect of electroacupuncture and moxibustion on the expression of substance P and vasoactive intestinal peptide in patients with irritable bowel syndrome

Evaluation of the effectiveness and mechanism of action of the Chang-Kang-Fang formula combined with bifid triple viable capsules on diarrhea-predominant irritable bowel syndrome

Specific probiotics and prebiotics to improve the quality of life of patients with chronic irritable bowel syndrome